Pfizer granted accelerated OK for Xalkori in NSCLC ahead of schedule

With the speed in which the US FDA has been approving new cancer drugs and the fact that the agency has OK'd three new therapies targeted at the disease this month well ahead of schedule leaves one to wonder if the head of the oncology drugs office had promised his staff the remainder of the summer off if they put the pedal to the metal.

In approving Pfizer's anaplastic lymphoma kinase (ALK) inhibitor Xalkori (crizotinib) on 26 August, the FDA also has for the second time this month cleared for marketing a cancer therapy along...